August 15, 2023 -- Clark, NJ -- The WBB Research Institute (WBBRI) recently hosted a two-part, 75-minute Demi-Colton Virtual Salon/Webinar on cell therapy and CAR-T, a breakthrough cancer treatment that modifies a patient’s own T-Cells to fight cancer. CAR-T and next generation cell therapies represent a considerable advance in oncology therapy.
Featured in the first part of the Webinar are two physician scientists on the frontier of this emerging medical technology - Doctors Helen Heslop and Malcolm Brenner from the Center for Cell and Gene Therapy at Baylor College of Medicine. They describe the current state of CAR-T therapy and ongoing research to enhance CAR-T and off-the-shelf cell therapy that can be used to treat any patient with any type of cancer.
Segment One begins with an introduction by Steve Brozak, CEO of WBB Securities and founder of WBBRI, followed with a video presentation by Dr. Heslop, describing the current state of CAR-T cell technology, clinical applications, and potential markets. Following the video, Dr. Brenner describes an approach to using CAR-T therapy for treating solid tumors, saying we need “an approach that deals with a tumor holistically, and one of the ways it might be possible to do that is by focusing not so much on the proteins that those tumors express but also on the whole tumor glycan (matrix).”
During the second segment of the Webinar, the CEOs of two biotechnology companies describe the latest developments in cell therapy treatments. Dr. Juan Vera describes how Marker Therapeutics (NASDAQ: MRKR) is working to advance novel T-Cell therapies for blood cancers and solid tumors, and Dr. Mark Frohlich of Indapta Therapeutics, describes his company’s efforts to develop an off-the-shelf universal cell therapy to treat cancer.
During this segment, Dr. Vera remarked on efforts to treat patients whose tumors are now resistant to CAR-T therapy. He said, “We envision that Marker’s multiple tumor-associated antigen (multiTAA) targeted therapy will be superior to treatment approaches targeting a single antigen, such as CAR-T cells.”
Doctor Frohlich spoke about another cell-based anti-cancer agent that has demonstrated high efficacy -- natural killer cells or NK cells. He said, “Our highly potent g-NK cells offer the potential for a new treatment for patients that is effective, safer, has a lower cost of goods, and can democratize access to these transformative therapies.”
Full recording is accessible through the link below:
https://virtualsalon.demy-colton.com/2023/07/13/car-t-cell-past-present-and-future/
The WBB Research Institute is a research organization, founded by WBB Securities. The Institute focuses on emerging critical issues in healthcare that threaten to have profound impact. WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused on the life sciences. WBB Securities is registered with the SEC as a broker-dealer, a FINRA member firm, and a Registered Investment Advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.
Demy-Colton
Demy Colton is a leader in biotech and life science events, with over 20 years of experience connecting leaders of innovative biotech companies with key stakeholders, investors, and advisors, we create ideal environments to examine and address opportunities and challenges in today’s biotech industry.
